

01/28/2019

ATTN:

Nuclear Regulatory Commission
Region III, Materials Licensing Branch
2443 Warrenville Rd., Ste. #210
Lisle, IL 60532-4352

RE: Amendment to NRC License No. 21-04177-01, Spectrum Health Lakeland.

Please amend the following items:

Please remove Thomas J. DeWind, M.D. and William F. Leahey, M.D. from our license as they no longer practice on this license. Also, please add Brendan Banyon, M.D. for 10 CFR 35.100, 200, and 300. His former NRC license practice is included for your reference. If there are any questions, please contact me at 269-985-4593, or by fax at 269-982-4937.

Sincerely,



David E. Sieffert, M.S., DABR
Medical Physicist
Radiation Safety Officer
Lakeland Medical Center
1234 Napier Ave.
St. Joseph, MI 49085
E-mail: dsieffert@lakelandhealth.org

RECEIVED JAN 28 2019

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 50

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Franciscan Health Michigan City 2. 301 W. Homer St. Michigan City, IN 46360		In accordance with letter dated August 08, 2018 3. License number: 13-13144-02 is amended in its entirety to read as follows:	4. Expiration Date: June 30, 2026 5. Docket No.: 030-09928 Reference No.:
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Iodine-125 permitted by 10 CFR 35.400	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Medi-Physics, Inc. d/b/a GE Healthcare, Model 6711 (OncoSeed))	8. Maximum amount that licensee may possess at any one time under this license A. As Needed B. As Needed C. 1 curie total D. 1 curie total	9. Authorized use A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200. C. For any use permitted by 10 CFR 35.300. D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

NRC FORM 374A		U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 OF 4 PAGES																		
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-13144-02	Docket or Reference Number 030-09928																			
	Amendment No. 50																				
CONDITIONS																					
10. Licensed material may be used or stored at the licensee's facilities located at: A. 301 W. Homer St., Michigan City, Indiana, 46360 B. 8955 W. 400 North, Michigan City, Indiana, 46360 C. 3500 N. Franciscan Way, Michigan City, Indiana, 46360																					
11. The Radiation Safety Officer (RSO) for this license is Richard L. Dobben, M.D.																					
12. Licensed material shall only be used by or under the supervision of: A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: <table border="1"> <thead> <tr> <th>Authorized User (M.D., D.O., etc.)</th> <th>Material and Use</th> </tr> </thead> <tbody> <tr> <td>Mohammed A. Abbas, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200</td> </tr> <tr> <td>Brendan Banyon, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)</td> </tr> <tr> <td>Richard L. Dobben, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)</td> </tr> <tr> <td>Michael Filsak, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.300</td> </tr> <tr> <td>Peter John Georgis, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300</td> </tr> <tr> <td>Perry M. Gilbert, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300</td> </tr> <tr> <td>Gregory Henkle, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)</td> </tr> <tr> <td>Joseph E. Judge, M.D.</td> <td>10 CFR 35.100, 10 CFR 35.200</td> </tr> </tbody> </table>				Authorized User (M.D., D.O., etc.)	Material and Use	Mohammed A. Abbas, M.D.	10 CFR 35.100, 10 CFR 35.200	Brendan Banyon, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)	Richard L. Dobben, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)	Michael Filsak, M.D.	10 CFR 35.100, 10 CFR 35.300	Peter John Georgis, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300	Perry M. Gilbert, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300	Gregory Henkle, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)	Joseph E. Judge, M.D.	10 CFR 35.100, 10 CFR 35.200
Authorized User (M.D., D.O., etc.)	Material and Use																				
Mohammed A. Abbas, M.D.	10 CFR 35.100, 10 CFR 35.200																				
Brendan Banyon, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)																				
Richard L. Dobben, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)																				
Michael Filsak, M.D.	10 CFR 35.100, 10 CFR 35.300																				
Peter John Georgis, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300																				
Perry M. Gilbert, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300																				
Gregory Henkle, M.D.	10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)																				
Joseph E. Judge, M.D.	10 CFR 35.100, 10 CFR 35.200																				

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 4 PAGES

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number
13-13144-02

Amendment No. 50

Docket or Reference Number
030-09928

Authorized User(M.D.,D.O., etc.)

Steven R. Klepac, M.D.

Jong-Il Marcus Lee, M.D.

A. Melinda Liller, M.D.

Garry Malnar, D.O.

Matthew J. Rose, M.D.

Mir J. Shah, M.D.

Michael A. Wilczynski, D.O.

Material and Use

10 CFR 35.100, 10 CFR 35.200

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)


10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.400

10 CFR 35.100, 10 CFR 35.200



NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 OF 4 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**


 License Number
13-13144-02

Amendment No. 50

 Docket or Reference Number
030-09928

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated December 8, 2015 (ML15344A470)
- B. Letter dated May 18, 2016 (ML16144A585)
- C. Letter dated May 15, 2017 (ML17139D193)
- D. Letter dated August 8, 2018 (ML18232A383)
- E. Letter dated September 20, 2018 (ML18264A054)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: OCT 31 2018By: B. A. Parker
 Bryan A. Parker
Region III



☒ Lakeland Medical Center
1234 Napier Avenue
St. Joseph, MI 49085-2158

☐ Lakeland Hospital, Niles
31 N. St. Joseph Avenue
Niles, MI 49120-2287

☐ Lakeland Hospital, Watervliet
400 Medical Park Drive
Watervliet, MI 49098

☐ Lakeland at Meadowbrook
2550 Meadowbrook Road
Benton Harbor, MI 49022

☐ Pine Ridge: A Rehabilitation and Nursing Center
4368 Cleveland Avenue
Stevensville, MI 49127

☐ Center for Outpatient Services
3900 Hollywood Road
St. Joseph, MI 49085

☐ Other _____

Fax Cover Sheet

To		From	
Name	NRC Region III	Name	David Sieffert
Location	materials licensing Div.	Location	RSD
Phone		Phone	269-985-4593
Fax	630-515-1078	Fax	269-982-4937

Message

Please amend our
license as requested.

Notice

The information accompanying this fax cover sheet is strictly confidential. It is intended only for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this facsimile transmission is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone, and return the original message to us at the above address via the U.S. Postal Service. Thank you.

Transmission

By		Date		Pages (including cover)	6
----	--	------	--	-------------------------	---